

International Consensus Guideline for Anticancer Drug Dosing in Kidney Dysfunction

May 2021



.....
Cancer Institute NSW

Rationale for guideline development



Inconsistencies in assessing and defining kidney function for drug dosing in cancer



Large variability in recommended dose adjustments in international guidelines and published studies




Limited evidence for dose adjustment in older anticancer drugs



Previous attempt by eviQ to standardise dose adjustments for organ dysfunction

Guideline development process



Conesus Recommendations from December 2020 National Workshop

1

Use eGFR via CKD-EPI to guide the assessment of kidney function, except when directly measured GFR is clinically necessary.

2

For anticancer drugs where the dose is dependent on kidney function, eGFR determined using CKD-EPI is suggested to guide dosing in the absence of a measured GFR.

3

KDIGO CKD categories are suggested to guide stepwise dose reductions of anticancer drugs in kidney dysfunction.